Workflow
The Oncology Institute(TOI) - 2025 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 10% year-over-year, reaching $104.4 million [5][13] - Gross profit for Q1 2025 was $17.2 million, representing a 44.1% increase compared to Q1 2024 [14] - Adjusted EBITDA loss was $5.1 million, an improvement from a loss of $10.9 million in Q1 2024 [15] - Net loss for the quarter was $19.6 million, an improvement of $303,000 compared to Q1 2024 [15] - Free cash flow was negative $3.9 million, compared to negative $15.4 million in Q1 2024 [16] Business Line Data and Key Metrics Changes - The Retail Pharmacy and Dispensary business generated $49.3 million in revenue, growing over 20% year-over-year [6] - Fee-for-service revenue grew by 2% year-over-year, reaching $35.6 million [13] - The dispensary segment saw a 24.2% growth, driven by increased prescription attachments to patient visits [13] Market Data and Key Metrics Changes - The company added over 80,000 lives under new capitation contracts in Q1 2025, with anticipated new contracts projected to add approximately $50 million in annualized revenue [6][19] - The company is focusing on expanding its presence in Florida, California, and Nevada markets [6] Company Strategy and Development Direction - The company aims for profitability and positive cash flow by the end of 2025, with a focus on operational management and strategic market expansion [5][22] - A new fully delegated capitation agreement in Florida is expected to enhance management capabilities and future opportunities [7] - The company is outsourcing its clinical trials program to Helios Clinical Trials to accelerate growth in existing and new markets [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance despite a projected $5 million reduction in revenue due to the outsourcing of clinical trials [19] - The company is closely monitoring potential impacts from tariffs and drug pricing regulations but currently does not anticipate negative effects on guidance [20][21] - Management highlighted a strong pipeline of new contracts and a commitment to maintaining SG&A expenses flat for 2025 [32] Other Important Information - The company successfully executed a partial paydown of $20 million in convertible preferred debt and raised $16 million in capital, strengthening its financial position [10] - The Chief Clinical Officer role was created to enhance the company's clinical capabilities in response to the evolving drug landscape [11] Q&A Session Summary Question: Can you talk about the gross profit growth of 44% year-over-year? - The growth was driven by a one-time rebate of $1.5 million and favorable drug pricing changes [26][28] Question: Can you discuss the fee-for-service revenue growth? - Fee-for-service revenue increased by 2% year-over-year, with a robust pipeline of new contracts expected to contribute to future growth [29][35] Question: What are the expectations for SG&A management in 2025? - The company aims to keep SG&A expenses roughly flat while seeking efficiencies through technology initiatives [32] Question: Are there any significant contract renewals coming up? - There are no significant renewals expected, as most relationships are multi-year and auto-renew [54] Question: How does the trend of delivering cancer care at home align with the company's business? - The company views this trend positively and is exploring innovative ways to deliver therapeutics in the home setting [56]